2d:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/0fma7nlq6immz.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/1chr5wkk3j58k.js","/_next/static/immutable/chunks/37kmmh_zm4dov.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2e:T5be7,

Summary Table

Category	Details
Risk Factors	Young adult women (ages 20 to 40), known or suspected multiple sclerosis, prior demyelinating episode, autoimmune background
Etiology	Most often associated with multiple sclerosis (MS). Other causes: neuromyelitis optica spectrum disorder (NMOSD), MOG-antibody disease, infections (syphilis, Lyme, viral), nutritional (vitamin B12 deficiency), toxic exposure (methanol, ethambutol)
Patient Presentation	Acute or subacute monocular vision loss developing over hours to days, pain that worsens with eye movement, color desaturation (especially red)
Classic Physical Exam	Decreased visual acuity, relative afferent pupillary defect (Marcus Gunn pupil), dyschromatopsia on Ishihara plates, normal optic disc on fundoscopy initially. Temporal optic disc pallor develops 4 to 6 weeks later
Key Diagnostic Results	MRI brain and orbits with gadolinium showing optic nerve enhancement and periventricular white matter lesions. Visual evoked potentials with prolonged P100 latency. Optical coherence tomography (OCT) shows retinal nerve fiber layer thinning over time
Management	IV methylprednisolone 1 g/day for 3 days, then oral prednisone 1 mg/kg/day for 11 days followed by a 4-day taper. Avoid oral prednisone monotherapy. Refer to neurology for disease-modifying therapy if MS criteria are met
Keywords	"Patient sees nothing, doctor sees nothing," painful eye movements, red desaturation, young woman, Marcus Gunn pupil, Uhthoff phenomenon

1. Pathophysiology

Retrobulbar neuritis is inflammation of the optic nerve at a segment located behind the globe. Because the inflamed portion of the nerve sits posterior to the optic disc, the optic disc looks completely normal on initial fundoscopy. This produces the classic teaching aphorism: the patient sees nothing and the examiner sees nothing. This finding directly distinguishes retrobulbar neuritis from papillitis, where the inflamed segment is at the optic nerve head and the disc appears swollen.

The dominant mechanism is T-cell mediated demyelination. Activated lymphocytes cross the blood-brain barrier, attack myelin sheaths, and create a conduction block along the optic nerve axons. This single process explains every cardinal feature seen in the vignette.

Vision loss results from impaired axonal signal transmission to the lateral geniculate nucleus and visual cortex. Pain with eye movement occurs because the inflamed optic nerve sheath shares fascial attachments with the superior rectus and medial rectus muscles; ocular movement physically tugs on the swollen, tender nerve. Dyschromatopsia with red desaturation reflects preferential dysfunction of small parvocellular fibers that mediate fine color discrimination, since these fibers are highly vulnerable to demyelinating injury. Relative afferent pupillary defect (RAPD) arises because the affected eye transmits a weaker afferent signal to the pretectal nucleus; on the swinging flashlight test, moving light from the healthy eye to the affected eye causes paradoxical pupil dilation.

Over the following weeks, demyelinated axons undergo secondary atrophy, producing temporal optic disc pallor by 4 to 6 weeks. The strong link with multiple sclerosis is grounded in the shared demyelinating mechanism. Optic neuritis is the presenting feature in roughly 20% of MS patients and occurs at some point in 50% to 70% of cases. Uhthoff phenomenon, transient visual blurring during exercise or hot showers, reflects heat-induced conduction failure in already demyelinated fibers and is a classic post-recovery feature.

2. Classification / Clinical Manifestation

Type	Site of Inflammation	Fundoscopy Findings	Typical Patient
Retrobulbar neuritis	Posterior to the globe	Normal disc initially	Young adult, strongly MS-associated
Papillitis	Optic nerve head	Swollen, hyperemic disc with blurred margins	More common in children
Neuroretinitis	Optic disc plus peripapillary retina	Disc swelling with macular star exudates	Often infectious (cat-scratch disease, Lyme)
Perineuritis	Optic nerve sheath	Disc swelling without major vision loss	Consider syphilis, sarcoidosis

Optic neuritis can also be classified by visual recovery pattern: typical demyelinating (good recovery, MS-associated), NMOSD-related (severe loss, poor recovery, aquaporin-4 antibody positive), and MOG-antibody disease (often bilateral, often steroid-responsive but relapsing).

3. Diagnostic Workup

Test	Purpose	Key Findings
Visual acuity, Ishihara plates	Bedside triage	Reduced acuity, red desaturation
Swinging flashlight test	Bedside	RAPD on the affected side
Fundoscopy	Rule out papillitis or papilledema	Normal disc initially in retrobulbar form
MRI brain and orbits with gadolinium	Most accurate test, MS risk stratification	T2 hyperintensity and contrast enhancement of optic nerve; periventricular and juxtacortical lesions
Visual evoked potentials (VEP)	Confirm demyelination	Prolonged P100 latency
Optical coherence tomography (OCT)	Track axonal loss	Retinal nerve fiber layer thinning
Lumbar puncture (selected cases)	Support MS diagnosis	Oligoclonal bands, elevated IgG index
Serology	Rule out mimics	Aquaporin-4 IgG, MOG antibody, RPR/VDRL, vitamin B12, ANA

Bedside evaluation begins with visual acuity, color plates, and the swinging flashlight test to confirm the RAPD. Fundoscopy is the best initial test to triage between retrobulbar neuritis (normal disc) and papillitis (swollen disc), since this finding alone distinguishes the two anatomic forms.

MRI of the brain and orbits with gadolinium contrast is the most accurate (gold standard) test. It demonstrates contrast enhancement of the affected optic nerve and, equally important, screens for demyelinating lesions in the periventricular white matter, juxtacortical regions, brainstem, and spinal cord that fulfill McDonald criteria for dissemination in space. The number of T2 lesions on the baseline MRI is the strongest predictor of conversion to clinically definite multiple sclerosis over the following 10 years; a normal baseline MRI gives roughly a 25% risk, while two or more lesions raise the risk to over 70%.

Visual evoked potentials reveal prolonged P100 latency and provide objective evidence of conduction delay even after vision recovers clinically, which is useful for documenting subclinical prior episodes. OCT quantifies retinal nerve fiber layer thinning and is increasingly used for longitudinal monitoring. Lumbar puncture is reserved for atypical presentations or to support an MS diagnosis when imaging is equivocal. Serologic testing for aquaporin-4 (NMOSD) and MOG antibodies is essential when the presentation is bilateral, severe, recurrent, or accompanied by transverse myelitis, because these conditions need different long-term immunotherapy.

4. Management & Treatment

Phase	Therapy	Dose	Duration
Acute	IV methylprednisolone	1 g/day	3 days
Taper	Oral prednisone	1 mg/kg/day	11 days, then 4-day taper
MS prevention	Disease-modifying therapy (interferon beta, glatiramer acetate, others)	Per neurology	Long-term
Refractory	Plasma exchange	Per neurology	For steroid-unresponsive cases

The cornerstone of acute treatment, established by the Optic Neuritis Treatment Trial, is intravenous methylprednisolone 1 gram once daily for three days, followed by oral prednisone 1 mg/kg/day for 11 days and a 4-day taper. This regimen speeds the rate of visual recovery, although it does not change the final visual acuity at one year. Oral prednisone alone, at conventional doses, is contraindicated because the original trial showed it increases the recurrence rate of optic neuritis without improving final visual outcomes.

The next best step after the diagnosis is established at the bedside is to initiate IV corticosteroids and to obtain an MRI brain and orbits with contrast if not already done, both to confirm diagnosis and to risk-stratify for MS. When the MRI shows two or more demyelinating lesions, the patient should be referred to neurology for early disease-modifying therapy, since early treatment delays conversion to clinically definite multiple sclerosis.

For patients with contraindications to high-dose steroids (uncontrolled diabetes, active infection, peptic ulcer disease, first-trimester pregnancy), individualized risk-benefit assessment is needed. In pregnancy, IV methylprednisolone may still be used in the second and third trimesters when vision loss is severe and threatens function. Plasma exchange is reserved for steroid-refractory cases and is particularly considered when NMOSD or MOG-antibody disease is suspected.

Long-term management focuses on the underlying demyelinating disorder. Most patients regain near-normal visual acuity within 4 to 6 weeks, although subtle deficits in color vision, contrast sensitivity, and depth perception (Pulfrich phenomenon) may persist. Uhthoff phenomenon, transient visual blurring with elevated body temperature or exercise, can recur for years and is not by itself a sign of clinical relapse; it should not be confused with a new attack.

5. Differential Diagnosis & Distractors

Differential Diagnosis	Why it's similar	Key Discriminator
Papillitis	Acute monocular vision loss with optic nerve inflammation	Optic disc is swollen and hyperemic on fundoscopy; more common in children
Non-arteritic anterior ischemic optic neuropathy (NAION)	Acute monocular vision loss with RAPD	Older patient (over 50), painless, altitudinal field defect, pale disc edema, history of vasculopathic risk factors (HTN, DM, OSA)
Arteritic AION (giant cell arteritis)	Sudden monocular vision loss in an older adult	Age over 50, headache, jaw claudication, scalp tenderness, elevated ESR/CRP, polymyalgia symptoms
Central retinal artery occlusion	Sudden monocular vision loss with RAPD	Painless, cherry-red spot with retinal whitening, onset within seconds
Central retinal vein occlusion	Acute monocular vision loss	Painless, "blood and thunder" fundus with diffuse retinal hemorrhages
Migraine with aura	Transient visual disturbance	Bilateral, fully reversible within 60 minutes, no RAPD, headache follows
Leber hereditary optic neuropathy	Painless subacute vision loss in a young patient	Young man, maternal inheritance, bilateral sequential involvement, mitochondrial DNA mutation
Toxic / nutritional optic neuropathy	Progressive vision loss	Bilateral and symmetric, central scotomas, history of methanol, ethambutol, isoniazid, or B12 deficiency
Functional vision loss	Vision loss without an obvious cause	Normal pupillary responses, normal MRI, inconsistent or tunnel-vision examination

6. Traps & High-Yield Pearls

The most common error is to anchor on papilledema or non-arteritic anterior ischemic optic neuropathy when a vignette describes acute monocular vision loss with an RAPD. The trap turns on three details: the patient's age, the presence of pain on eye movement, and the appearance of the optic disc. A young woman with painful eye movements and a normal fundus is retrobulbar neuritis until proven otherwise. An older adult with painless vision loss and a pale, swollen disc is anterior ischemic optic neuropathy; if it is accompanied by headache or jaw claudication, treat empirically for giant cell arteritis with high-dose steroids before biopsy results return.

A second classic gotcha is the management question that lists "oral prednisone" as a tempting choice. Remember the lesson from the Optic Neuritis Treatment Trial: standard-dose oral prednisone alone raises the rate of recurrence. The correct sequence is IV methylprednisolone first, then an oral taper.

A third trap is the recurrent or bilateral presentation. When a stem describes severe bilateral vision loss, longitudinally extensive transverse myelitis, or recurrent optic neuritis with poor recovery, do not lock in on multiple sclerosis. Think neuromyelitis optica spectrum disorder (aquaporin-4 antibody) or MOG-antibody disease, both of which require different long-term immunotherapy and may need plasma exchange acutely.

A fourth pitfall is missing toxic or nutritional optic neuropathy. When vision loss is bilateral, painless, gradual, and accompanied by central scotomas, look for ethambutol use in a patient on tuberculosis therapy, methanol exposure, or B12 deficiency. These patients do not need IV methylprednisolone; they need removal of the offending agent or replacement of the missing nutrient.

The core competency being tested is pattern recognition of the classic triad (acute monocular vision loss, painful eye movements, dyschromatopsia in a young woman with a normal fundus) combined with correct sequencing of the workup (bedside examination first, then MRI brain and orbits with contrast as the confirmatory test) and the right pharmacologic plan (IV methylprednisolone, never oral prednisone alone).

1e:["$","$L2d",null,{"article":{"id":"59c5d1ef-9aae-4b8b-b26f-accaaed75a1f","title":"Optic Neuritis","content":"$2e","category":"Oftalmologi","created_at":"2026-04-29T02:47:35.539619+00:00","status":"published","subcategory":null},"questionCount":0,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-clinical-manifestation","num":"02","title":"Classification / Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-treatment","num":"04","title":"Management & Treatment"},{"id":"section-differential-diagnosis-distractors","num":"05","title":"Differential Diagnosis & Distractors"},{"id":"section-traps-high-yield-pearls","num":"06","title":"Traps & High-Yield Pearls"}],"hasSummaryTable":true}]